News
1d
Zacks.com on MSNCVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?CVS stock surges nearly 50% in 2025, aided by strong Q1 results, raised guidance and easing Medicare regulation risks.
10h
Dealbreaker on MSNNew Bipartisan Bill from Rep. Carter Aims to Crack Down on Pharmacy Benefit ManagersA bill introduced by Rep. Buddy Carter would ban PBMs’ use of spread pricing in Medicaid, among other reforms.
While major pharmacy benefit management reform was stripped out of the Big Beautiful Bill, a bipartisan group of ...
14d
960 The Ref on MSNCVS Caremark drops Zepbound coverage for Wegovy for weight lossThis change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...
U.S. Reps. Raja Krishnamoorthi, D-Ill., and Earl “Buddy” Carter, R-Ga., along with nine other representatives, introduced a ...
Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...
CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...
Cigna's announcement follows CVS Caremark designating Wegovy as its preferred weight loss drug last month.
Pharmacy benefit manager CVS Caremark decided to replace Zepbound with Wegovy for use in weight loss starting July 1, despite Zepbound users having more weight loss success.
Last month, CVS Caremark announced that it had struck a deal to make Novo's Wegovy its primary weight loss drug starting in the second half of the year, which would mean coverage for Lilly's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results